The FDA Needs a New Boss. Nobody Knows Who It'll Be.
The FDA hasn't had a permanent commissioner since May, and the White House is reviewing finalists to lead an agency that's lost 20% of its workforce. The choice will shape drug approval standards, AI-driven review pilots, and biotech valuations for years to come.
The most powerful job in American drug regulation is sitting empty, and the White House is auditioning replacements like it's casting for a reboot nobody asked for.
The FDA hasn't had a permanent commissioner since Marty Makary resigned in May 2026. Acting Commissioner Kyle Diamantas is keeping the lights on, but a short list of finalists has now landed on the president's desk. The question isn't just who gets the job. It's whether the agency can survive the wait.
The Candidates Read Like a Mad Libs
Three names have been formally sent to the White House for review, according to Bloomberg: Heidi Overton, Jeffrey Vacirca, and Stephen Ferrara. Beyond them, a handful of other contenders keep showing up in analyst notes and political gossip columns.
Overton is considered the frontrunner. She's a physician with a background in military health policy and currently serves as a deputy assistant to the president for domestic policy. RBC Capital Markets describes her as the "more likely" pick, though the bank also notes she's not on record championing pro-innovation FDA programs like compressed review timelines or single-trial approvals. She's not against them either. She's just a question mark, which is exactly what makes investors nervous.
Then there's John Crowley, the CEO of BIO (the Biotechnology Innovation Organization) and a former rare-disease biotech CEO. Crowley is the industry's dream candidate: vocal about faster approvals, fewer regulatory barriers, and keeping U.S. biotech competitive with China. RBC calls his potential impact on biopharma "likely very positive," especially for rare disease companies. The catch? His deep industry ties would almost certainly trigger a bruising Senate confirmation fight. Think of it like hiring your favorite restaurant's head chef to run the health department; the food might be great, but people will have questions.
Vacirca, a practicing oncologist and health system executive, brings strong clinical credibility. Ferrara, a senior DOD health affairs official, brings experience managing large, complex systems. Both are serious candidates, though neither has generated the same volume of analyst speculation.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Meanwhile, the Placeholder Might Stick Around
Kyle Diamantas, the acting commissioner, was the FDA's top food official before stepping into the big chair. He's a lawyer by training, not a drug development expert, and analysts at RBC consider it "unlikely" he'll become the permanent pick. But here's the wrinkle: the Senate calendar is packed, and the HELP Committee (chaired by Sen. Bill Cassidy, whose relationship with the White House is, let's say, complicated) has other health nominations to process.
Administration officials have said the search would take "the next several weeks." Multiple analysts think Diamantas could still be running the show when voters head to the polls in November. Under federal rules, he can serve as acting commissioner for up to 210 days, potentially stretching into early December.
For biotech companies waiting on approval decisions, that's not comforting. Historically, leadership vacuums at the FDA correlate with slower decisions and greater unpredictability. And this particular vacuum comes at the worst possible time.
An Agency Running on Fumes
The FDA lost roughly 3,500 employees in 2025, about 20% of its entire workforce. That number includes layoffs, buyouts, retirements, and voluntary exits. The drug review center (CDER) alone shed over 1,000 staff in a single fiscal year, erasing all hiring gains from the previous two years.
The departures weren't random. They were concentrated at the top: the heads of drug evaluation, biologics, the oncology center of excellence, the chief medical officer, even the chief AI officer. BioSpace called 2025 "a catastrophic year" for FDA personnel, and the remaining staff are widely described as demoralized.
Remarkably, FDA reviewers still met nearly all of their user-fee deadlines for the 46 novel drugs approved in 2025. But that performance came under enormous strain, and capacity concerns are mounting for 2026 and beyond. It's like a restaurant that lost half its kitchen staff but kept putting out dishes on time; the food still came, but nobody wanted to look too closely at how.
The Real Stakes for Biotech
The next commissioner won't just be filling a chair. They'll be deciding the future of several policy experiments that Makary launched before he left.
Makary pushed hard on AI-assisted drug reviews, real-world data integration, and reforms to Phase 1 clinical trials (the earliest human tests of new drugs). He created pilot programs, appointed an AI chief, and tried to compress timelines wherever possible. Since his departure, the agency has pulled back from that aggressive pace. Comment periods have been extended. Pilots have slowed. The AI office is leaderless.
A commissioner like Crowley might hit the accelerator again, streamlining approvals and championing innovation. A pick like Overton might take a more measured, evidence-first approach. An extended Diamantas era would likely mean continuity: stable but unambitious, a caretaker holding the wheel steady without changing direction.
For small and mid-cap biotechs, the distinction matters enormously. These are companies whose entire valuations can swing on a single FDA decision date. Uncertainty about who's making that decision and what standards they'll apply is its own kind of risk.
What to Watch
The confirmation process itself will be telling. Any nominee needs to clear the Senate HELP Committee and then survive a full Senate vote. Candidates with strong industry connections (Crowley, most obviously) can expect the same scrutiny that dogged Robert Califf over his pharma ties and Janet Woodcock over her role during the opioid crisis. Those fights took months.
RBC and other analysts recommend watching for two signals: the official White House announcement and early Senate reactions. Those will reveal whether the next FDA leader means incremental continuity or a real shift in how drugs get reviewed, approved, and brought to patients.
Until then, the most important regulatory agency in medicine is being run by a food-policy lawyer with a 210-day clock, an agency that's lost a fifth of its workforce, and an industry that's trying very hard to be patient.
The auditions continue.
Deals & M&A5 min read
GSK Just Lit $700 Million on Fire (and Walked Away)
GSK just terminated its $2.2 billion Alzheimer's partnership with Alector after both drugs flopped in clinical trials. The $700 million upfront payment is gone forever, and the wreckage tells us a lot about why the brain remains drug development's toughest frontier.
